MedTrace Logo

A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)

NCT06680817 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 850

Last updated 2026-05-11

No results posted yet for this study

Summary

The FaReal study aims to evaluate the effectiveness, safety, clinical insights and treatment patterns in patients treated with faricimab, in neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) in at least one eye, in real-world routine clinical practice over a 2-year patient follow-up period. Additionally, the FaReal study also aims to describe and evaluate health economic aspects of previous anti-VEGF treatments and current treatment with faricimab.

Conditions

Interventions

DRUG

Faricimab

Faricimab will be administered as per local clinical practice and local labeling.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-05
Primary Completion
2027-06-30
Completion
2028-06-30

Countries

  • Austria
  • Bulgaria
  • Czechia
  • Finland
  • Greece
  • Hungary
  • Ireland
  • Israel
  • Latvia
  • Netherlands
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06680817 on ClinicalTrials.gov